Highlight
- EBV-positive diffuse large B-cell lymphoma (EBV⁺DLBCL) patients exhibit profound systemic impairments in antiviral T-cell responses affecting both EBV and non-EBV viral antigens.
- The tumor microenvironment in EBV⁺DLBCL is markedly immunosuppressive, characterized by loss of intratumoural CD8⁺ T cells and expansion of PD-1⁺ exhausted and regulatory T-cell populations.
- Dense aggregates of PD-L1⁺/IDO1⁺ macrophages form suppressive myeloid niches preferentially surrounding LMP1-expressing tumor cells, a unique feature distinct from other EBV-associated lymphoid conditions.
- The convergence of systemic antiviral immune dysfunction and LMP1-driven myeloid immunosuppression underpins the aggressive clinical behavior and poor outcomes of EBV⁺DLBCL.
Study Background
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and exhibits heterogeneous clinical outcomes. Epstein-Barr virus-positive DLBCL (EBV⁺DLBCL) is a distinct and aggressive variant frequently linked to poor prognosis. Traditionally, its pathogenesis has been attributed to immunosenescence, explaining its higher incidence in older adults due to declining immune surveillance. However, the occurrence of EBV⁺DLBCL across all age groups challenges this explanation and suggests alternative immunobiological mechanisms driving its development and progression. Understanding the interplay between host antiviral immunity and the local tumor microenvironment is critical for developing therapeutic strategies tailored to EBV⁺DLBCL’s unique biology.
Study Design
This integrative study combined several advanced methodologies to dissect the immunobiology of EBV⁺DLBCL. Functional profiling of peripheral antiviral T-cell immunity was performed comparing EBV⁺DLBCL and EBV-negative (EBV⁻) DLBCL patients with healthy controls, assessing T-cell responses against latent and lytic EBV antigens as well as non-EBV viral targets. High-dimensional spatial proteomic analysis was applied to tumor tissues to characterize the composition, localization, and functional phenotype of immune cells within the tumor microenvironment. Additionally, mechanistic in vitro modeling further elucidated the role of EBV-encoded latent membrane protein 1 (LMP1) in modulating the immune milieu. Comparator groups included EBV⁺ classical Hodgkin lymphoma (cHL) and infectious mononucleosis to contextualize EBV⁺DLBCL’s immunosuppressive signature.
Key Findings
The study documented a broad and profound loss of systemic antiviral T-cell immunity in both EBV⁺ and EBV⁻DLBCL patients relative to healthy individuals, with the most significant deficits observed in the EBV⁺DLBCL group. The antiviral T-cell impairment affected responses to latent EBV antigens such as EBNA1 and lytic cycle proteins, as well as other common viral targets, reflecting a generalized deterioration of the antiviral immune repertoire rather than a virus-specific phenomenon.
Spatial proteomic analysis revealed that EBV⁺DLBCL harbors a profoundly immunosuppressive tumor microenvironment distinct from EBV⁺cHL and infectious mononucleosis. Key features included:
– A significant reduction of intratumoural cytotoxic CD8⁺ T-cell density, compromising direct antitumor immunity.
– Expansion of PD-1⁺ CD4⁺ regulatory T cells and exhausted T-cell populations, indicative of dysfunctional immune surveillance.
– Dense aggregates of macrophages co-expressing PD-L1 and indoleamine 2,3-dioxygenase 1 (IDO1), forming suppressive myeloid niches that contribute to immune escape mechanisms.
Importantly, these suppressive myeloid niches were preferentially enriched in regions surrounding LMP1-expressing tumor cells—a finding that was not observed in EBV⁺ cHL or infectious mononucleosis. LMP1, an EBV-encoded oncogenic protein, appears to orchestrate local immune suppression by fostering these myeloid cell aggregates, thus directly contributing to the immunological landscape in EBV⁺DLBCL.
In vitro mechanistic studies supported that LMP1 expression drives the recruitment and activation of immunosuppressive macrophages, enhancing PD-L1 and IDO1 levels and promoting an environment conducive to T-cell exhaustion and evasion of antiviral and antitumor immune responses.
Expert Commentary
This comprehensive study elucidates a dual mechanism underlying the aggressive phenotype of EBV⁺DLBCL: a systemic collapse of antiviral T-cell immunity combined with localized immunosuppression driven by LMP1-associated myeloid niches. It challenges the simplistic model of immunosenescence as the main causative factor and highlights the tumor’s ability to actively subvert immune control both systemically and locally.
From a therapeutic standpoint, these findings underscore the potential value of targeting immune checkpoints such as PD-1/PD-L1 axis and IDO1 pathways in combination with strategies to restore systemic antiviral immunity. The preferential enrichment of suppressive macrophages around LMP1-expressing tumor cells raises the prospect of designing LMP1-specific interventions or macrophage-modulating therapies to break the immune suppressive cycle.
Limitations include the observational nature of the human sample analyses and the need for further clinical validation of therapeutic hypotheses generated. Moreover, the heterogeneity of immune defects between patients calls for personalized biomarker-driven approaches.
Conclusion
EBV⁺DLBCL represents a complex immunobiological entity driven by the combined effects of systemic antiviral immune dysfunction and an LMP1-mediated immunosuppressive tumor microenvironment. This convergence not only explains the poor clinical outcomes but also opens new avenues for therapeutic intervention targeting both systemic and local immune defects. Future research should focus on translating these insights into clinical trials incorporating immune checkpoint inhibitors, IDO1 inhibitors, and novel agents targeting LMP1-associated pathways to improve prognosis in this high-risk lymphoma subtype.
Funding and ClinicalTrials.gov
Details regarding funding sources and trial registrations were not specified in the original publication.
References
1. Fennell É, Law SC, Dowell AC, et al. Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma. Leukemia. 2026 Jun 10. PMID: 42271039.
2. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004 Oct;4(10):757-68.
3. Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005 Apr;5(4):251-62.
4. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK-STAT signaling in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010 Nov 18;116(17):3268-77.
5. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013 Jul 1;19(13):3462-73.
6. Vail E, Slobedman B, Abendroth A. Identification of EBV recombinant mutant viruses expressing functional latent membrane protein 1 and encoded microRNAs. Curr Protein Pept Sci. 2015 Mar;16(2):128-38.
